Le Lézard
Classified in: Health
Subject: SVY

Synthetic Bone Graft Substitutes - Medical Devices Pipeline Assessment, 2017



LONDON, Oct. 6, 2017 /PRNewswire/ -- Summary



Download the full report: https://www.reportbuyer.com/product/4465333


GlobalData's Medical Devices sector report, "Synthetic Bone Graft Substitutes - Medical Devices Pipeline Assessment, 2017" provides an overview of Synthetic Bone Graft Substitutes currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Synthetic Bone Graft Substitutes pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
- Extensive coverage of the Synthetic Bone Graft Substitutes under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Synthetic Bone Graft Substitutes and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Synthetic Bone Graft Substitutes under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date

Download the full report: https://www.reportbuyer.com/product/4465333

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com  

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 01:15
SANTA ROSA, Calif., Oct. 17, 2017 /PRNewswire/ -- Sutter Santa Rosa Regional Hospital announced today that it will reopen with full services at 7 a.m. on Tuesday, Oct. 17? just eight days after the hospital was evacuated during the devastating Tubbs...

16 oct 2017
COLUMBUS, Ga., Oct. 16, 2017 /PRNewswire/ -- Aflac Incorporated announced today that it has priced ¥60 billion (par value) in yen-denominated subordinated debentures with a coupon of 2.108%. The subordinated debentures will mature in 2047 and are...

16 oct 2017
LAVAL, Quebec, Oct. 16, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant...

16 oct 2017
NEW YORK, Oct. 16, 2017 /PRNewswire-USNewswire/ -- Two renowned Parkinson's disease and movement disorders physician-researchers have been appointed co-executive directors of the Marlene and Paolo Fresco Institute for Parkinson's and Movement...

16 oct 2017
HERTFORDSHIRE, England, and PITTSBURGH, Oct. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United States District Court for the Eastern District of Texas has issued a 135-page decision finding all asserted claims of...

16 oct 2017
LOS ANGELES, Oct. 16, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Nasdaq has granted the Company's request for a continued listing pending...




News published on 6 october 2017 at 09:56 and distributed by: